CARBIDOPA AND LEVODOPA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Carbidopa And Levodopa, and when can generic versions of Carbidopa And Levodopa launch?
Carbidopa And Levodopa is a drug marketed by Accord Hlthcare, Alembic, Apotex, Impax Labs, Kv Pharm, Mylan, Sciegen Pharms Inc, Sun Pharm Inds, Rising, Sun Pharm, Actavis Elizabeth, Ani Pharms, Apotex Inc, Aurobindo Pharma Ltd, Dr Reddys Labs Sa, Rubicon, SCS, Watson Labs, and Zydus Pharms. and is included in twenty-seven NDAs.
The generic ingredient in CARBIDOPA AND LEVODOPA is carbidopa; levodopa. There are eighteen drug master file entries for this compound. Thirty-three suppliers are listed for this compound. Additional details are available on the carbidopa; levodopa profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Carbidopa And Levodopa
A generic version of CARBIDOPA AND LEVODOPA was approved as carbidopa; levodopa by DR REDDYS LABS SA on August 28th, 1992.
Summary for CARBIDOPA AND LEVODOPA
US Patents: | 0 |
Applicants: | 19 |
NDAs: | 27 |
Finished Product Suppliers / Packagers: | 29 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Clinical Trials: | 183 |
Patent Applications: | 580 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CARBIDOPA AND LEVODOPA |
DailyMed Link: | CARBIDOPA AND LEVODOPA at DailyMed |
Recent Clinical Trials for CARBIDOPA AND LEVODOPA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bronx VA Medical Center | Phase 1 |
VistaGen Therapeutics, Inc. | Phase 2 |
University of Minnesota | Early Phase 1 |
Pharmacology for CARBIDOPA AND LEVODOPA
Drug Class | Aromatic Amino Acid |
Anatomical Therapeutic Chemical (ATC) Classes for CARBIDOPA AND LEVODOPA
US Patents and Regulatory Information for CARBIDOPA AND LEVODOPA
EU/EMA Drug Approvals for CARBIDOPA AND LEVODOPA
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Amneal Pharma Europe Ltd | Numient | levodopa, carbidopa | EMEA/H/C/002611 Symptomatic treatment of adult patients with Parkinson’s disease |
Withdrawn | no | no | no | 2015-11-19 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |